 USA Today | Abbott Executive Sees Some Pipeline Drugs With Yearly Sales Over $1B Wall Street Journal However, several of these drugs, including daclizumab, may not make it to market until around 2015, assuming successful clinical trials and regulatory approval. And as with any experimental drug, it's possible that some won't make it to market if they ... Abbott Reports Strong Ongoing Third Quarter Results; Confirms Double-Digit ... Abbott Laboratories' CEO Discusses Q3 2011 Results - Earnings Call Transcript The Abbott Break-Up Seems To Make Sense (ABT, BIIB, BMY) |
